Trial Profile
A study to evaluate the total and regional pulmonary deposition of the fluticasone propionate/formoterol using two-dimensional gamma scintigraphy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2017
Price :
$35
*
At a glance
- Drugs Formoterol/fluticasone propionate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Mundipharma Research
- 15 Sep 2017 Results presented at the European Respiratory Society 2017.
- 15 Sep 2017 New trial record
- 09 Sep 2017 Results published in a Mundipharma media release.